NOVOCURE ($NVCR) posted quarterly earnings results for Q4 2025 on Thursday, February 26th. The company reported earnings of -$0.22 per share, beating estimates of -$0.42 by $0.20. The company also reported revenue of $174,350,000, missing estimates of $176,821,804 by $-2,471,804.
You can see Quiver Quantitative's $NVCR stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
NOVOCURE Insider Trading Activity
NOVOCURE insiders have traded $NVCR stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $NVCR stock by insiders over the last 6 months:
- ASHLEY CORDOVA (Chief Executive Officer) purchased 81,550 shares for an estimated $996,859
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
NOVOCURE Hedge Fund Activity
We have seen 146 institutional investors add shares of NOVOCURE stock to their portfolio, and 139 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 4,555,996 shares (-95.3%) from their portfolio in Q4 2025, for an estimated $58,909,028
- MORGAN STANLEY added 4,153,741 shares (+453.4%) to their portfolio in Q4 2025, for an estimated $53,707,871
- CAPITAL WORLD INVESTORS removed 2,000,000 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $25,860,000
- JACOBS LEVY EQUITY MANAGEMENT, INC added 1,121,192 shares (+1093.2%) to their portfolio in Q4 2025, for an estimated $14,497,012
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 1,114,207 shares (-11.6%) from their portfolio in Q4 2025, for an estimated $14,406,696
- MARSHALL WACE, LLP removed 1,034,978 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $13,382,265
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 942,283 shares (-99.7%) from their portfolio in Q4 2025, for an estimated $12,183,719
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
NOVOCURE Government Contracts
We have seen $9,257,400 of award payments to $NVCR over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- EXPRESS REPORT: OPTUNE PLUS TRANSDUCERS: $149,246
- OPTUNE PLUS TRANSDUCERS: $99,497
- OPTUNE TRANSDUCER (6 MONTH RENTAL): $99,497
- PROS TRANSDUCERS: $99,497
- PROSTHETICS. OPTUNE DEVICE.: $99,497
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
NOVOCURE Analyst Ratings
Wall Street analysts have issued reports on $NVCR in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 02/12/2026
To track analyst ratings and price targets for NOVOCURE, check out Quiver Quantitative's $NVCR forecast page.
NOVOCURE Price Targets
Multiple analysts have issued price targets for $NVCR recently. We have seen 3 analysts offer price targets for $NVCR in the last 6 months, with a median target of $23.0.
Here are some recent targets:
- Emily Bodnar from HC Wainwright & Co. set a target price of $47.0 on 02/12/2026
- David Nierengarten from Wedbush set a target price of $18.0 on 01/15/2026
- Jessica Fye from JP Morgan set a target price of $23.0 on 10/27/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
